117 research outputs found
Recommended from our members
Analysis of retinotectal regeneration in goldfish using polar dimensions: temporal sequence and spatial order
Quantitative analysis of electrophysiological visuotectal maps using polar dimensions demonstrated uniform representation of visual field on goldfish optic tectum, with topography equally precise in normal and "mature" regenerated projections. The precision of circumferential topography exceeds and is not correlated with that of radial. Radial orderliness may he poor without diminution of circumferential order: these two dimensions of pattern could he generated separately from each other. The method of analysis also allows quantitation of the orientation of the retinotectal projection.
During development radial retinotopy in the sequence of axon growth could contribute to radial topography by confining optic terminals to specific annuli within the projection. The possibility of pattern formation by this means during regeneration was studied by examining the sequence of fibre growth by retrograde labelling of ganglion cells with horseradish peroxidase (HRP), applied to a cut through the optic tract at successive intervals after optic nerve transection in mid-orbit. Most results indicated a central-to-peripheral sequence of regeneration; others showed absence of retinotopic sequence.
Regeneration of axons from central retina was delayed by repetition of axotomy. Subsequent visuotectal maps were either normal or included electrophysiologically weak representation of central visual field on peripheral tectum, outside or superimposed upon the map of peripheral field. Some of the abnormal maps also contained normal representation of central field on central tectum. Because of the contradictions in these results, the influence of temporal sequence on spatial order of connections remains uncertain.
Formation of circumferential topography was investigated by anterograde tracing with HRP of axons from narrow sectors of retina in normal and regenerated pathways. Juxtaposition of labelled axons appears to be completely lost in the optic chiasm or at the site of optic nerve transection. Contact guidance of axons therefore cannot explain circumferential order in the map. Labelling was inadequate to show whether regenerating fibres resegregate retinotopically in the optic tract
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
Background and Objectives. Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS).
Study AB07002 assessed oral masitinib in patients with progressive MS who were progressing but not clinically active.
Methods. This randomized, double-blind, 2 parallel-group, placebo-controlled trial assessing 2 dose levels
of masitinib vs equivalent placebo was conducted at 116 hospital clinics and specialized MS centers in 20 countries. Randomization (2:1) with minimization was performed centrally using an automated system. Patients, physicians, and outcome assessors remained masked to treatment group allocation. Patients with primary progressive MS (PPMS) or nonactive secondary progressive MS (nSPMS) without relapse for â„2 years, aged 18â75 years, with baseline Expanded Disability Status Scale (EDSS) 2.0â6.0, and regardless of time from onset were treated for 96 weeks. The primary end point was overall EDSS change from baseline using repeated measures (generalized estimating equation, timeframe W12âW96, measured every 12 weeks), with positive values indicating increased clinical deterioration. Efficacy and safety were assessed in all randomly assigned and treated patients.
Results. A total of 611 patients were randomized; 301 in the masitinib 4.5 mg/kg/d parallel group and
310 in the uptitrated masitinib 6.0 mg/kg/d parallel group. Masitinib (4.5 mg/kg/d) (n = 199) showed significant benefit over placebo (n = 101) according to the primary end point, 0.001 vs 0.098, respectively, with a between-group difference of â0.097 (97% CI â0.192 to â0.002); p =0.0256. Safety was consistent with masitinibâs known profile (diarrhea, nausea, rash, and hematologic events), with no elevated risk of infection. Efficacy results from the independent uptitrated masitinib 6.0 mg/kg/d parallel group were inconclusive, and no new safety signal was observed.
Discussion. Masitinib (4.5 mg/kg/d) can benefit people with PPMS and nSPMS. A confirmatory phase 3
study will be initiated to substantiate these data
Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
International audienceBackground: Tyrosine kinases are attractive targets for pancreatic cancer therapy because several are over-expressed, including PDGFRα/ÎČ, FAK, Src and Lyn. A critical role of mast cells in the development of pancreatic cancer has also been reported. Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGFRα/ÎČ, Lyn, and to a lesser extent the FAK pathway, without inhibiting kinases of known toxicities. Masitinib is particularly efficient in controlling the proliferation, differentiation and degranulation of mast cells. This study evaluates the therapeutic potential of masitinib in pancreatic cancer, as a single agent and in combination with gemcitabine.Methodology/Findings: Proof-of-concept studies were performed in vitro on human pancreatic tumour cell lines and then in vivo using a mouse model of human pancreatic cancer. Molecular mechanisms were investigated via gene expression profiling. Masitinib as a single agent had no significant antiproliferative activity while the masitinib/gemcitabine combination showed synergy in vitro on proliferation of gemcitabine-refractory cell lines Mia Paca2 and Panc1, and to a lesser extent in vivo on Mia Paca2 cell tumour growth. Specifically, masitinib at 10 ”M strongly sensitised Mia Paca2 cells to gemcitabine (>400-fold reduction in IC50); and moderately sensitised Panc1 cells (10-fold reduction). Transcriptional analysis identified the Wnt/ÎČ-catenin signalling pathway as down-regulated in the cell lines resensitised by the masitinib/gemcitabine combination.Conclusions: These data establish proof-of-concept that masitinib can sensitise gemcitabine-refractory pancreatic cancer cell lines and warrant further in vivo investigation. Indeed, such an effect has been recently observed in a phase 2 clinical study of patients with pancreatic cancer who received a masitinib/gemcitabine combination
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of <1.1 points/month. Here we assess long-term overall survival (OS) data of all participants from study AB10015 and test whether a signal in OS is evident in an enriched patient population similar to that prospectively defined for confirmatory study AB19001. Methods: Survival status of all patients originally randomized in AB10015 was collected from participating investigational sites. Survival analysis (using the multivariate log-rank test and Cox proportional hazards model, with stratification factors as covariates) was performed on the intention-to-treat population and enriched subgroups, which were defined according to initial randomization, baseline ALSFRS-R progression rate and baseline disease severity. Results: A significant survival benefit of 25 months (p = 0.037) and 47% reduced risk of death (p = 0.025) was observed for patients receiving 4.5 mg/kg/day masitinib (n = 45) versus placebo (n = 62) in an enriched cohort with â©Ÿ2 on each baseline ALSFRS-R individual component score (i.e. prior to any complete loss or severe impairment of functionality) and post-onset ALSFRS-R progression rate <1.1 (i.e. exclusion of very fast progressors) [median OS of 69 versus 44 months, respectively; hazard ratio, 0.53 [95% CI (0.31â0.92)]]. This corresponds to the population enrolled in confirmatory phase III study, AB19001. Conclusions: Analysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality.Fil: Mora, Jesus S.. No especifĂca;Fil: Bradley, Walter G.. University of Miami; Estados UnidosFil: Chaverri, Delia. No especifĂca;Fil: HernĂĄndez Barral, MarĂa. No especifĂca;Fil: Mascias, Javier. No especifĂca;Fil: Gamez, Josep. Universitat AutĂČnoma de Barcelona; EspañaFil: Gargiulo Monachelli, Gisella Mariana. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones MĂ©dicas e Investigaciones ClĂnicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Moussy, Alain. No especifĂca;Fil: Mansfield, Colin D.. No especifĂca;Fil: Hermine, Olivier. No especifĂca;Fil: Ludolph, Albert C.. Universitat Ulm; Alemani
Evidence for overwintering and autochthonous transmission of Usutu virus to wild birds following its redetection in the United Kingdom
Usutu virus (USUV) is an emerging zoonotic arbovirus in Europe, where it primarily impacts Eurasian blackbirds (Turdus merula). For mosquito-borne viruses to persist in temperate areas, transovarial transmission in vectors or overwintering in either hosts or diapausing vectors must occur to facilitate autochthonous transmission. We undertook surveillance of hosts and vectors in 2021 to elucidate whether USUV had overwintered in the United Kingdom (UK) following its initial detection there in 2020. From 175 dead bird submissions, we detected 1 case of USUV infection, in a blackbird, from which a full USUV genome was derived. Using a molecular clock analysis, we demonstrate that the 2021 detection shared a most recent common ancestor with the 2020 Greater London, UK, USUV sequence. In addition, we identified USUV-specific neutralizing antibodies in 10 out of 86 serum samples taken from captive birds at the index site, demonstrating in situ cryptic infection and potential sustained transmission. However, from 4966 mosquitoes, we detected no USUV RNA suggesting that prevalence in the vector community was absent or low during sampling. Combined, these results suggest that USUV overwintered in the UK, thus providing empirical evidence for the continued northward expansion of this vector-borne viral disease. Currently, our detection indicates geographically restricted virus persistence. Further detections over time will be required to demonstrate long-term establishment. It remains unclear whether the UK, and by extension other high-latitude regions, can support endemic USUV infection
Bringing the Kingdom to the city:mission and the place-making practices among Kenyan Pentecostals in London
Kenyan Pentecostals in London (re)frame their migration as a âmissionâ to bring the United Kingdom back into the Kingdom of God. Focusing on the case of one church founded in the diaspora, this article examines how the pastor and church members try to realize this mission by exploring the kind of place they imagine Godâs Kingdom to be and their efforts to create it in London. The âspatial turnâ in studies of religion has followed two general trajectories, broadly referred to as the politics and the poetics of space. Studies of Pentecostal placemaking in particular have examined how Pentecostals use churchâplanting as a strategy of territorialization, by which they make their presence seen and felt in specific localities, as well as how they phenomenologically âdoâ space. This article contributes to these discussions by elucidating a particular form of sociality as an important aspect of religious placemaking. In doing so, I argue that Pentecostal projects of selfâmaking and placemaking converge in what I refer to as âsocializing space.â At the same time, through its focus on an independent church, the article extends our understanding of African diasporic churches beyond the wellâstudied and âresourced transnational African Pentecostal networks and megachurches. [Pentecostalism; Placemaking; London; Kenya; African Diaspora
Reflections on a crisis: political disenchantment, moral desolation, and political integrity
Declining levels of political trust and voter turnout, the shift towards populist politics marked by appeals to âthe peopleâ and a rejection of âpolitics-as-usualâ, are just some of the commonly cited manifestations of our culture of political disaffection. Democratic politics, it is argued, is in crisis. Whilst considerable energy has been expended on the task of lamenting the status of our politics and pondering over recommendations to tackle this perceived crisis, amid this raft of complaints and solutions lurks confusion. This paper seeks to explore the neglected question of what the precise nature of the crisis with which we are confronted involves, and, in so doing, to go some way towards untangling our confusion. Taking my cue from Machiavelli and his value-pluralist heirs, I argue that there is a rift between a morally admirable and a virtuous political life. Failure to appreciate this possibility causes narrations of crisis to misconstrue the moral messiness of politics in ways that lead us to misunderstand how we should respond to disenchantment. Specifically, I suggest that: (i) we think that there is a moral crisis in politics because we have an unsatisfactorily idealistic understanding of political integrity in the first place; and (ii) it is a mistake to imagine that the moral purification of politics is possible or desirable. Put simply, our crisis is not moral per se but primarily philosophical in nature: it relates to the very concepts we employâthe qualities of character and context we presuppose whilst pondering over political integrity
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
International audienceBackground: The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT. Methodology/Principal Findings: In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory concentration (IC50) of 200 ± 40 nM and blocking stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC50 of 150 ± 80 nM in Ba/F3 cells expressing human or mouse wild-type KIT. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies. Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib. Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain. In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant. Conclusions: Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicit
Recommended from our members
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohnâs disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
Objective: Thiopurines are widely used as maintenance therapy in inflammatory bowel disease (IBD) but the evidence base for their use is sparse and their role increasingly questioned. Using the largest series reported to date, we assessed the long-term effectiveness of thiopurines in ulcerative colitis (UC) and Crohnâs disease (CD), including their impact on need for surgery. Design: Outcomes were assessed in 11 928 patients (4968 UC, 6960 CD) in the UK IBD BioResource initiated on thiopurine monotherapy with the intention of maintaining medically induced remission. Effectiveness was assessed retrospectively using patient-level data and a definition that required avoidance of escalation to biological therapy or surgery while on thiopurines. Analyses included overall effectiveness, time-to-event analysis for treatment escalation and comparison of surgery rates in patients tolerant or intolerant of thiopurines. Results: Using 68 132 patient-years of exposure, thiopurine monotherapy appeared effective for the duration of treatment in 2617/4968 (52.7%) patients with UC compared with 2378/6960 (34.2%) patients with CD (p<0.0001). This difference was corroborated in a multivariable analysis: after adjusting for variables including treatment era, thiopurine monotherapy was less effective in CD than UC (OR 0.47, 95% CI 0.43 to 0.51, p<0.0001). Thiopurine intolerance was associated with increased risk of surgery in UC (HR 2.44, p<0.0001); with a more modest impact on need for surgery in CD (HR=1.23, p=0.0015). Conclusion: Thiopurine monotherapy is an effective long-term treatment for UC but significantly less effective in CD
- âŠ